Expected Immune Recognition of COVID-19 Virus by Memory from Earlier Infections with Common Coronaviruses in a Large Part of the World Population

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2020 Jul 31

PMID 32595955

Citations 14

Authors

Johannes M Dijkstra

Keiichiro Hashimoto

Affiliations

Soon will be listed here.

Abstract

SARS-CoV-2 is the coronavirus agent of the COVID-19 pandemic causing high mortalities. In contrast, the widely spread human coronaviruses OC43, HKU1, 229E, and NL63 tend to cause only mild symptoms. The present study shows, by analysis, that these common human viruses are expected to induce immune memory against SARS-CoV-2 by sharing protein fragments (antigen epitopes) for presentation to the immune system by MHC class I. A list of such epitopes is provided. The number of these epitopes and the prevalence of the common coronaviruses suggest that a large part of the world population has some degree of specific immunity against SARS-CoV-2 already, even without having been infected by that virus. For inducing protection, booster vaccinations enhancing existing immunity are less demanding than primary vaccinations against new antigens. Therefore, for the discussion on vaccination strategies against COVID-19, the available immune memory against related viruses should be part of the consideration.

Citing Articles

Cross-reactivity influences changes in human influenza A virus and Epstein Barr virus specific CD8 memory T cell receptor alpha and beta repertoires between young and old.

Clark F, Gil A, Thapa I, Aslan N, Ghersi D, Selin L Front Immunol. 2023; 13():1011935.

PMID: 36923729 PMC: 10009332. DOI: 10.3389/fimmu.2022.1011935.

Association between the Seroprevalence of Antibodies against Seasonal Alphacoronaviruses and SARS-CoV-2 Humoral Immune Response, COVID-19 Severity, and Influenza Vaccination.

Brydak L, Sikora D, Poniedzialek B, Hallmann E, Szymanski K, Kondratiuk K J Clin Med. 2023; 12(5).

PMID: 36902520 PMC: 10003754. DOI: 10.3390/jcm12051733.

HLA-dependent variation in SARS-CoV-2 CD8 T cell cross-reactivity with human coronaviruses.

Buckley P, Lee C, Pinho M, Ottakandathil Babu R, Woo J, Antanaviciute A Immunology. 2022; 166(1):78-103.

PMID: 35143694 PMC: 9111820. DOI: 10.1111/imm.13451.

mRNA COVID-19 Vaccines and Long-Lived Plasma Cells: A Complicated Relationship.

Giannotta G, Giannotta N Vaccines (Basel). 2021; 9(12).

PMID: 34960249 PMC: 8703557. DOI: 10.3390/vaccines9121503.

MHC Variants Associated With Symptomatic Asymptomatic SARS-CoV-2 Infection in Highly Exposed Individuals.

Castelli E, de Castro M, Naslavsky M, Scliar M, Silva N, Andrade H Front Immunol. 2021; 12:742881.

PMID: 34650566 PMC: 8506217. DOI: 10.3389/fimmu.2021.742881.

References

Polakos N, Drane D, Cox J, Ng P, Selby M, Chien D . Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine. J Immunol. 2001; 166(5):3589-98. DOI: 10.4049/jimmunol.166.5.3589. View

Zhao J, Zhao J, Mangalam A, Channappanavar R, Fett C, Meyerholz D . Airway Memory CD4(+) T Cells Mediate Protective Immunity against Emerging Respiratory Coronaviruses. Immunity. 2016; 44(6):1379-91. PMC: 4917442. DOI: 10.1016/j.immuni.2016.05.006. View

Weingartl H, Czub M, Czub S, Neufeld J, Marszal P, Gren J . Immunization with modified vaccinia virus Ankara-based recombinant vaccine against severe acute respiratory syndrome is associated with enhanced hepatitis in ferrets. J Virol. 2004; 78(22):12672-6. PMC: 525089. DOI: 10.1128/JVI.78.22.12672-12676.2004. View

Braun J, Loyal L, Frentsch M, Wendisch D, Georg P, Kurth F . SARS-CoV-2-reactive T cells in healthy donors and patients with COVID-19. Nature. 2020; 587(7833):270-274. DOI: 10.1038/s41586-020-2598-9. View

Liu W, Zhao M, Liu K, Xu K, Wong G, Tan W . T-cell immunity of SARS-CoV: Implications for vaccine development against MERS-CoV. Antiviral Res. 2016; 137:82-92. PMC: 7113894. DOI: 10.1016/j.antiviral.2016.11.006. View

Kaml M, Weiskirchner I, Keller M, Luft T, Hoster E, Hasford J . Booster vaccination in the elderly: their success depends on the vaccine type applied earlier in life as well as on pre-vaccination antibody titers. Vaccine. 2006; 24(47-48):6808-11. DOI: 10.1016/j.vaccine.2006.06.037. View

Du L, Zhao G, Lin Y, Sui H, Chan C, Ma S . Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against.... J Immunol. 2008; 180(2):948-56. PMC: 2603051. DOI: 10.4049/jimmunol.180.2.948. View

Vijgen L, Keyaerts E, Moes E, Thoelen I, Wollants E, Lemey P . Complete genomic sequence of human coronavirus OC43: molecular clock analysis suggests a relatively recent zoonotic coronavirus transmission event. J Virol. 2005; 79(3):1595-604. PMC: 544107. DOI: 10.1128/JVI.79.3.1595-1604.2005. View

Zhao J, Zhao J, Perlman S . T cell responses are required for protection from clinical disease and for virus clearance in severe acute respiratory syndrome coronavirus-infected mice. J Virol. 2010; 84(18):9318-25. PMC: 2937604. DOI: 10.1128/JVI.01049-10. View

10.

Killerby M, Biggs H, Haynes A, Dahl R, Mustaquim D, Gerber S . Human coronavirus circulation in the United States 2014-2017. J Clin Virol. 2018; 101:52-56. PMC: 7106380. DOI: 10.1016/j.jcv.2018.01.019. View

11.

Thiel V, Herold J, Schelle B, Siddell S . Infectious RNA transcribed in vitro from a cDNA copy of the human coronavirus genome cloned in vaccinia virus. J Gen Virol. 2001; 82(Pt 6):1273-1281. DOI: 10.1099/0022-1317-82-6-1273. View

12.

Zhou P, Yang X, Wang X, Hu B, Zhang L, Zhang W . A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature. 2020; 579(7798):270-273. PMC: 7095418. DOI: 10.1038/s41586-020-2012-7. View

13.

Weiss S, Navas-Martin S . Coronavirus pathogenesis and the emerging pathogen severe acute respiratory syndrome coronavirus. Microbiol Mol Biol Rev. 2005; 69(4):635-64. PMC: 1306801. DOI: 10.1128/MMBR.69.4.635-664.2005. View

14.

Tang F, Quan Y, Xin Z, Wrammert J, Ma M, Lv H . Lack of peripheral memory B cell responses in recovered patients with severe acute respiratory syndrome: a six-year follow-up study. J Immunol. 2011; 186(12):7264-8. DOI: 10.4049/jimmunol.0903490. View

15.

Nguyen A, David J, Maden S, Wood M, Weeder B, Nellore A . Human Leukocyte Antigen Susceptibility Map for Severe Acute Respiratory Syndrome Coronavirus 2. J Virol. 2020; 94(13). PMC: 7307149. DOI: 10.1128/JVI.00510-20. View

16.

Schellens I, Hoof I, Meiring H, Spijkers S, Poelen M, van Gaans-van den Brink J . Comprehensive Analysis of the Naturally Processed Peptide Repertoire: Differences between HLA-A and B in the Immunopeptidome. PLoS One. 2015; 10(9):e0136417. PMC: 4574158. DOI: 10.1371/journal.pone.0136417. View

17.

Arnold P, La Gruta N, Miller T, Vignali K, Scott Adams P, Woodland D . The majority of immunogenic epitopes generate CD4+ T cells that are dependent on MHC class II-bound peptide-flanking residues. J Immunol. 2002; 169(2):739-49. DOI: 10.4049/jimmunol.169.2.739. View

18.

Qiu T, Mao T, Wang Y, Zhou M, Qiu J, Wang J . Identification of potential cross-protective epitope between a new type of coronavirus (2019-nCoV) and severe acute respiratory syndrome virus. J Genet Genomics. 2020; 47(2):115-117. PMC: 7111282. DOI: 10.1016/j.jgg.2020.01.003. View

19.

Nielsen M, Lundegaard C, Lund O, Kesmir C . The role of the proteasome in generating cytotoxic T-cell epitopes: insights obtained from improved predictions of proteasomal cleavage. Immunogenetics. 2005; 57(1-2):33-41. DOI: 10.1007/s00251-005-0781-7. View

20.

Schulze K, Staib C, Schatzl H, Ebensen T, Erfle V, Guzman C . A prime-boost vaccination protocol optimizes immune responses against the nucleocapsid protein of the SARS coronavirus. Vaccine. 2008; 26(51):6678-84. PMC: 7115531. DOI: 10.1016/j.vaccine.2008.09.006. View